at Investor's Business Daily (Mon, 6:42PM)
Mylan (MYL -0.1%) says its subsidiary Mylan Pharmaceuticals has reached a settlement with Shionogi and Andrx to resolve patent litigation related to the generic version of Shionogi's Fortamet, an adjunct to diet and exercise to lower blood glucose. The terms of the settlement agreement are confidential, but has been disclosed it that MYL may launch a generic version of Fortamet on August 1, 2013, or earlier under certain conditions.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Nasdaq.com (Jan 21, 2015)
at Zacks.com (Jan 12, 2015)
at Zacks.com (Jan 9, 2015)
at Zacks.com (Jan 7, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs